Functionalized solid lipid nanoparticles combining docetaxel and erlotinib synergize the anticancer efficacy against triple-negative breast cancer

[Display omitted] The goal of the study was to fabricate folic acid functionalized docetaxel (DOC)/erlotinib (ERL)-loaded solid lipid nanoparticles (SLNs) to synergistically increase the anticancer activity against triple-negative breast cancer. DOC/ERL-SLNs were prepared by the high shear homogeniz...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmaceutics and biopharmaceutics 2024-08, Vol.201, p.114386, Article 114386
Main Authors: Chaudhuri, Aiswarya, Naveen Kumar, Dulla, Kumar, Dinesh, Kumar Agrawal, Ashish
Format: Article
Language:English
Subjects:
Docetaxel
Erlotinib
Folic acid
Quality-by-Design (QbD)
Solid lipid nanoparticles
Triple-negative breast cancer
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] The goal of the study was to fabricate folic acid functionalized docetaxel (DOC)/erlotinib (ERL)-loaded solid lipid nanoparticles (SLNs) to synergistically increase the anticancer activity against triple-negative breast cancer. DOC/ERL-SLNs were prepared by the high shear homogenization – ultrasound dispersion method (0.1 % w/v for DOC, and 0.3 %w/v for ERL) and optimized using Plackett Burman Design (PBD) followed by Box Behnken Design (BBD). The optimized SLNs demonstrated particle size 
ISSN:0939-6411
1873-3441
1873-3441
DOI:10.1016/j.ejpb.2024.114386